7 Review of guidance

7.1 The guidance on this technology will be considered for review in February 2014. This is to coincide with the review date proposed for NICE technology appraisal guidanceĀ 155 (ranibizumab and pegaptanib for the treatment of ageā€‘related macular degeneration). The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
July 2013

  • National Institute for Health and Care Excellence (NICE)